Cargando…
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
BACKGROUND: Trastuzumab emtansine (T-DM1) has demonstrated improvements in survival and neurological symptoms in patients with breast cancer with brain metastases (BCBM). This real-world study investigated the effectiveness of T-DM1 versus lapatinib plus capecitabine (LC) in patients with BCBM. METH...
Autores principales: | Sanglier, Thibaut, Shim, Jinjoo, Lamarre, Neil, Peña-Murillo, Claudia, Antao, Vincent, Montemurro, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300572/ https://www.ncbi.nlm.nih.gov/pubmed/36709091 http://dx.doi.org/10.1016/j.breast.2023.01.007 |
Ejemplares similares
-
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
por: Cortés, Javier, et al.
Publicado: (2020) -
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA(†)
por: Krop, I. E., et al.
Publicado: (2015) -
T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022) -
Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021) -
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)